ADVISORY, April 05, 2016 --
What:
Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Terry Winters, Co-chairman, and Chief Executive Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Wednesday, April 6, 2016 – 9:15 a.m. to 9:30 a.m. ET
Vital Therapies Media Contact:
Al Kildani
(858) 673-6840
[email protected]
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq
For livestream of ceremonies and events visit our YouTube Page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit our Tumblr Page:
http://nasdaq.tumblr.com/
Webcast: A LiveStream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-


TSMC Posts Record Q1 Profit Fueled by AI Chip Demand
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO
CATL Stock Hits Record High After Q1 2025 Earnings Surge
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 



